Generic and specialty pharmaceuticals Mylan has introduced its pressurised metered-dose inhaler (pMDI), Sirdupla, in the UK.
Sirdupla is a generic version of GlaxoSmithKline’s (GSK) Seretide Evohaler (salmeterol xinafoate/fluticasone propionate), which is indicated to treat or prevent symptoms of asthma in adults.
Mylan president Rajiv Malik said: "Mylan is excited to be the first company to offer adult asthma patients in the UK the generic version of Seretide Evohaler, delivering on our mission to increase access to high-quality medicine.
"Sirdupla represents a significant advancement for the company that both strengthens our respiratory portfolio and pipeline, and further demonstrates our ability to successfully execute on one of our key strategic growth drivers."
Sirdupla is a daily maintenance pressurised metered-dose inhaler that is available in 125/25mcg and 250/25 mcg with 120 doses.
3M Drug Delivery Systems will manufacture the generic version of GSK’s asthma therapy.
Mylan said that it is the first firm to sell a generic version of the UK’s number one prescribed long-acting beta2-agonist plus inhaled corticosteroid pressurised metered-dose inhaler asthma therapy.
3M Drug Delivery Systems general manager and president Cindy Kent said: "3M will fill, assemble and package Sirdupla at 3M’s manufacturing facility in Loughborough, UK. By partnering with Mylan, 3M has taken an important step forward in the generics space."
Mylan has a portfolio of around 1,400 generic pharmaceuticals and several brand medications. It also provides a wide range of antiretroviral therapies, including for HIV/AIDS, in developing countries.